

Margaret E Black

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3905059/publications.pdf>

Version: 2024-02-01

35
papers

1,382
citations

471509

17
h-index

477307

29
g-index

35
all docs

35
docs citations

35
times ranked

1380
citing authors

#	ARTICLE	IF	CITATIONS
1	Computational Thermostabilization of an Enzyme. <i>Science</i> , 2005, 308, 857-860.	12.6	337
2	The structure of Escherichia coli cytosine deaminase 1 Edited by I. A. Wilson. <i>Journal of Molecular Biology</i> , 2002, 315, 687-697.	4.2	135
3	Phase I Dose Escalation Clinical Trial of Adenovirus Vector Carrying Osteocalcin Promoter-Driven Herpes Simplex Virus Thymidine Kinase in Localized and Metastatic Hormone-Refractory Prostate Cancer. <i>Human Gene Therapy</i> , 2003, 14, 227-241.	2.7	125
4	The 1.14 Å... Crystal Structure of Yeast Cytosine Deaminase. <i>Structure</i> , 2003, 11, 961-972.	3.3	88
5	Characterization of Herpes Simplex Virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity. <i>Protein Science</i> , 2009, 11, 2267-2272.	7.6	88
6	Identification of important residues within the putative nucleoside binding site of HSV-1 thymidine kinase by random sequence selection: Analysis of selected mutants in vitro. <i>Biochemistry</i> , 1993, 32, 11618-11626.	2.5	67
7	Enhanced Ganciclovir Killing and Bystander Effect of Human Tumor Cells Transduced with a Retroviral Vector Carrying a Herpes Simplex Virus Thymidine Kinase Gene Mutant. <i>Human Gene Therapy</i> , 2000, 11, 1569-1576.	2.7	56
8	Random mutagenesis and selection of Escherichia coli cytosine deaminase for cancer gene therapy. <i>Protein Engineering, Design and Selection</i> , 2004, 17, 625-633.	2.1	55
9	Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing. <i>Cancer Gene Therapy</i> , 2003, 10, 353-364.	4.6	53
10	Alanine-Scanning Mutagenesis Reveals a Cytosine Deaminase Mutant with Altered Substrate Preference. <i>Biochemistry</i> , 2004, 43, 8957-8964.	2.5	42
11	Cloning, Characterization, and Modeling of Mouse and Human Guanylate Kinases. <i>Journal of Biological Chemistry</i> , 1996, 271, 16734-16740.	3.4	41
12	Optimizing Prostate Cancer Suicide Gene Therapy Using Herpes Simplex Virus Thymidine Kinase Active Site Variants. <i>Human Gene Therapy</i> , 2002, 13, 777-789.	2.7	40
13	Bacterial Cytosine Deaminase Mutants Created by Molecular Engineering Show Improved 5-Fluorocytosine-Mediated Cell Killing <i>in vitro</i> and <i>in vivo</i> . <i>Cancer Research</i> , 2009, 69, 4791-4799.	0.9	39
14	Yeast Cytosine Deaminase Mutants with Increased Thermostability Impart Sensitivity to 5-Fluorocytosine. <i>Journal of Molecular Biology</i> , 2008, 377, 854-869.	4.2	38
15	Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2845-2854.	4.1	27
16	Enzymes To Die For: Exploiting Nucleotide Metabolizing Enzymes for Cancer Gene Therapy. <i>Current Gene Therapy</i> , 2012, 12, 77-91.	2.0	26
17	Titration of Variant HSV1-tk Gene Expression to Determine the Sensitivity of ¹⁸ F-FHBC PET Imaging in a Prostate Tumor. <i>Journal of Nuclear Medicine</i> , 2009, 50, 757-764.	5.0	20
18	Hypoxia theranostics of a human prostate cancer xenograft and the resulting effects on the tumor microenvironment. <i>Neoplasia</i> , 2020, 22, 679-688.	5.3	16

#	ARTICLE	IF	CITATIONS
19	Development and validation of a rapid and sensitive HPLC method for the quantification of 5-Fluorocytosine and its metabolites. <i>Biomedical Chromatography</i> , 2010, 24, 556-561.	1.7	13
20	The mouse guanylate kinase double mutant E72Q/D103N is a functional adenylate kinase. <i>Protein Engineering, Design and Selection</i> , 2001, 14, 903-909.	2.1	10
21	Development of Inhibitor-Directed Enzyme Prodrug Therapy (IDEPT) for Prostate Cancer. <i>Bioconjugate Chemistry</i> , 2014, 25, 1752-1760.	3.6	10
22	The Role of Herpes Simplex Virus-1 Thymidine Kinase Alanine 168 in Substrate Specificity. <i>The Open Biochemistry Journal</i> , 2008, 2, 60-66.	0.5	10
23	Crystallization and preliminary X-ray analysis of bacterial cytosine deaminase. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2001, 57, 1643-1645.	2.5	8
24	A novel <i>Escherichia coli</i> strain allows functional analysis of guanylate kinase drug resistance and sensitivity. <i>Analytical Biochemistry</i> , 2003, 322, 40-47.	2.4	7
25	Mutations at serine 37 in mouse guanylate kinase confer resistance to 6-thioguanine. <i>Protein Engineering, Design and Selection</i> , 2009, 22, 225-232.	2.1	7
26	Targeted Delivery of DNA Encoding Cytotoxic Proteins through High-Affinity Fibroblast Growth Factor Receptors. <i>Human Gene Therapy</i> , 1998, 9, 2565-2575.	2.7	6
27	Enzyme and Pathway Engineering for Suicide Gene Therapy. , 2001, 23, 113-127.		5
28	Random Sequence Mutagenesis for the Generation of Active Enzymes. , 1996, 57, 335-350.		4
29	Optimization of Thymidine Kinase-Based Safety Switch for Neural Cell Therapy. <i>Cells</i> , 2022, 11, 502.	4.1	4
30	Enhancement of Suicide Gene Prodrug Activation by Random Mutagenesis. , 2004, 90, 331-344.		2
31	Creation of zebularine-resistant human cytidine deaminase mutants to enhance the chemoprotection of hematopoietic stem cells. <i>Protein Engineering, Design and Selection</i> , 2016, 29, gzw012.	2.1	2
32	Validation of an isocratic HPLC method to detect 2-fluoro- β -alanine for the analysis of dihydropyrimidine dehydrogenase activity. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 1889-1892.	2.3	1
33	930. Engineering Human Deoxycytidine Kinase for Improved Prodrug Sensitivity for Cancer Gene Therapy. <i>Molecular Therapy</i> , 2006, 13, S359.	8.2	0
34	925. Novel Fusion Enzymes of Herpes Simplex Virus Thymidine Kinase Mutants and Guanylate Kinase for Improved Cancer Cell Ablation. <i>Molecular Therapy</i> , 2006, 13, S357.	8.2	0
35	Evaluation of a UCMK/dCK fusion enzyme for gemcitabine-mediated cytotoxicity. <i>Biochemical and Biophysical Research Communications</i> , 2011, 416, 199-204.	2.1	0